Journal
EXPERT REVIEW OF CARDIOVASCULAR THERAPY
Volume 10, Issue 3, Pages 337-351Publisher
TAYLOR & FRANCIS INC
DOI: 10.1586/ERC.12.5
Keywords
arteriosclerosis; cardiovascular risk; dipeptidyl peptidase-4; DPP-4 inhibitor; endothelial function; GLP-1 agonist; glucagon-like peptide-1; incretin
Categories
Funding
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Lilly
- Merck
- Novartis
- Novo Nordisk
Ask authors/readers for more resources
Glucagon-like peptide (GLP)-1 agonists and dipeptidyl peptidase-4 inhibitors are two classes of drugs that have been approved for treatment of Type 2 diabetes mellitus, based upon the glucose-lowering actions of the gastrointestinal hormone GLP-1. However, GLP-1 receptors are also present in cardiovascular tissues. Data from animal and in vitro studies suggest that GLP-1 may have cardioprotective effects and improve myocardial and endothelial dysfunction. Clinical data demonstrating cardiovascular effects are more limited, and there is some evidence that incretin-based therapies may be associated with improvements in cardiovascular risk factors. Large prospective cardiovascular outcome trials are underway to examine the cardiovascular safety of incretin-based therapies, and may reveal whether these agents are associated with any reduction in cardiovascular adverse events in patients with Type 2 diabetes mellitus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available